Teva Pharmaceutical Revenue, Profits - TEVA Quarterly Income Statement

Add to My Stocks
$17.68 $0.23 (1.28%) TEVA stock closing price Mar 20, 2018 (Closing)

Fundamental analysis of TEVA stock involves analyzing its financial statements, apart from checking the Teva Pharmaceutical stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $5.46B for 2017 Q4 impacts the TEVA stock. Investors typically check year over year or quarter over quarter revenue growth. The Teva Pharmaceutical profit and loss statement for 2017 Q4 shows a net profit of $-11.54B. Profits for last year was $595M. Apart from this an investor should also check Teva Pharmaceutical assets and Teva Pharmaceutical free cash flow.

View and download details of revenue and profits for Teva Pharmaceutical for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Teva Pharmaceutical Revenues or Net Sales
Cost Of Goods Sold (COGS)-2.97B2.87B2.81B3.1B2.76B2.16B2.02B2.03B2.05B
Teva Pharmaceutical Gross Profit
Research & Development Expense-545M486M457M684M663M375M389M446M361M
Selling General & Admin Expense-1.17B1.56B1.23B1.67B1.78B1.43B1.12B1.31B1.02B
Income Before Depreciation Depletion Amortization-928M779M1.14B1.04B355M1.07B1.28B1.09B1.39B
Depreciation Depletion Amortization--6.1B-900M-----
Non Operating Income--809M-657M-447M-1.06B260M-817M-417M-233M-1.08B
Interest Expense----------
Teva Pharmaceutical Pretax Income
Provision for Income Taxes--494M-22M54M57M207M29M228M249M193M
Investment Gains Losses--3M-14M7M-3M2M15M-6M-114M-4M
Other Income----------
Income Before Extraordinaries & Disc Operations-11.54B595M-5.97B645M-973M412M254M636M485M103M
Extraordinary Items & Discontinued Operations----------
Teva Pharmaceutical Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS1.02B1.02B1.02B1.02B1.02B984M979M920M875M862M
Average Shares used to compute Basic EPS1.02B1.02B1.02B1.02B1.02B979M914M913M866M851M
Income Before Nonrecurring Items997.1M991.2M1B1.11B1.46B1.33B1.23B1.15B1.12B1.17B
Income from Nonrecurring Items-12.53B-396.2M-6.97B-469.12M-2.43B-922.66M-974M-512M-636M-1.06B
Teva Pharmaceutical Earnings Per Share Basic Net
Teva Pharmaceutical Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.910.950.991.031.361.
Preferred Dividends Acc Pd-66.16M--------
Dividends Common73.4173.36--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Teva Pharmaceutical stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Teva Pharmaceutical revenue chart, implies that the company is growing. It has not been the case with Teva Pharmaceutical. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Teva Pharmaceutical try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the TEVA income statement, one can check the Teva Pharmaceutical historical stock prices to check how the price has moved with time.

Teva Pharmaceutical Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield